Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | NQO1 | P15559 | 3/20 | 0.33 |
| ▸ | CTRC | Q99895 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
| ▸ | BAD | Q92934 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332145 | 0.82 | HIF1A (0.55) | CES1HIF1AEPAS1 | |
| SCHEMBL3336228 | 0.74 | CES1 (0.45) | CES1PARP1HIF1AEPAS1CYP19A1 | |
| SCHEMBL16939655 | 0.73 | CES1 (0.62) | CES1PARP1HIF1AEPAS1CYP19A1 | |
| SCHEMBL11647580 | 0.70 | ALDH1A1 (0.53) | ELANE | |
| SCHEMBL939289 | 0.70 | DNMT1 (0.46) | CES1ELANEHIF1A | |
| SCHEMBL1077250 | 0.69 | GABRA1 (0.40) | CES1PARP1NQO1CTRCBCL2L1 | |
| SCHEMBL3290440 | 0.69 | GABRA1 (0.44) | ELANENQO1CTRCBCL2L1BAD | |
| SCHEMBL939989 | 0.69 | APAF1 (0.54) | ELANEHIF1A | |
| SCHEMBL3330344 | 0.68 | MAPT (0.45) | CES1PARP1HIF1AHTR1A | |
| SCHEMBL3333080 | 0.68 | HSP90AA1 (0.35) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404869-B2 | Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome | MAZENCE INC. (KR) | 2013-03-26 | — | — | US | disclosed |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | YUNGJIN PHARM. CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | CYP27A1, CYP46A1, PCSK9 | CES1 131/4885PARP1 2487/4885ELANE 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.